Skip to main content
Top
Published in: Medical Oncology 12/2014

01-12-2014 | Original Paper

Two polymorphisms of USF1 gene (−202G>A and −844C>T) may be associated with hepatocellular carcinoma susceptibility based on a case–control study in Chinese Han population

Authors: Xu Zhou, Hua-qiang Zhu, Chao-qun Ma, Hong-guang Li, Fang-feng Liu, Hong Chang, Jun Lu

Published in: Medical Oncology | Issue 12/2014

Login to get access

Abstract

Hepatocellular carcinoma (HCC) is a prototype of liver cancer, which is closely related to manifested metabolism of lip and glucose. Upstream transcription factor 1 (USF1) is an important transcription factor in human genome, and it regulates the expression of multiple genes associated with lipid and glucose metabolism. This study aims at investigating the correlation between seven common USF1 polymorphisms (i.e., −1994G>A, −202G>A, 7998A>G, −844C>T, 9042C>G, 9441T>C, and −2083G>A) and the risk of HCC. Elucidation of the interaction might be of vital importance to the diagnosis and prognosis of HCC. One hundred and fifty-five HCC patients and 160 healthy controls from a Chinese Han population were involved in this study. Tag single-nucleotide polymorphisms (SNPs) were identified with reference to CBI-dbSNP and HapMap databases. DNA was extracted from blood samples, and matrix-assisted laser desorption–ionization time-of-flight mass spectrometry (MALDI-TOF–MS) was conducted to determine the polymorphisms of USF1. Odds ratio (OR) and 95 % confidence interval were applied to evaluate the difference of genotype distribution. Seven SNPs were selected to be representatives. No significant difference was observed concerning −1994G>A, 7998A>G, 9042C>G, 9441T>C, and −2083G>A polymorphisms (all P > 0.05). A significantly elevated genotype frequency regarding −202G>A polymorphism was observed in HCC patients [AA vs. GG: OR 2.13 (1.13–4.01), P = 0.019; AA vs. GG+GA: OR 2.22 (1.32–3.75), P = 0.003; A allele vs. G allele: OR 1.46 (1.07–2.01), P = 0.018]. Subjects carrying mutant −844C>T genotypes also had a higher risk of HCC [CT vs. CC: OR 1.88 (1.17–3.04), P = 0.009; CT+TT vs. CC: OR 1.83 (1.17–2.86), P = 0.008; T allele vs. C allele: OR 1.49 (1.06–2.09), P = 0.020]. Further studies are recommended to validate our findings in different ethnicity and to clarify the functional relationship between USF1 polymorphisms and the susceptibility of HCC.
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
3.
go back to reference Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis. 2010;30(4):391–401.PubMedCrossRef Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis. 2010;30(4):391–401.PubMedCrossRef
4.
go back to reference Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56(4):952–64.PubMedCrossRef Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56(4):952–64.PubMedCrossRef
5.
go back to reference Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820–32.PubMedCrossRef Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820–32.PubMedCrossRef
7.
go back to reference Gaddikeri S, McNeeley MF, Wang CL, Bhargava P, Dighe MK, Yeh MM, et al. Hepatocellular carcinoma in the noncirrhotic liver. AJR Am J Roentgenol. 2014;203(1):11511.CrossRef Gaddikeri S, McNeeley MF, Wang CL, Bhargava P, Dighe MK, Yeh MM, et al. Hepatocellular carcinoma in the noncirrhotic liver. AJR Am J Roentgenol. 2014;203(1):11511.CrossRef
8.
go back to reference Baron Y, Corre S, Mouchet N, Vaulont S, Prince S, Galibert MD. USF-1 is critical for maintaining genome integrity in response to UV-induced DNA photolesions. PLoS Genet. 2012;8(1):26.CrossRef Baron Y, Corre S, Mouchet N, Vaulont S, Prince S, Galibert MD. USF-1 is critical for maintaining genome integrity in response to UV-induced DNA photolesions. PLoS Genet. 2012;8(1):26.CrossRef
9.
go back to reference Ribeiro A, Pastier D, Kardassis D, Chambaz J, Cardot P. Cooperative binding of upstream stimulatory factor and hepatic nuclear factor 4 drives the transcription of the human apolipoprotein A-II gene. J Biol Chem. 1999;274(3):1216–25.PubMedCrossRef Ribeiro A, Pastier D, Kardassis D, Chambaz J, Cardot P. Cooperative binding of upstream stimulatory factor and hepatic nuclear factor 4 drives the transcription of the human apolipoprotein A-II gene. J Biol Chem. 1999;274(3):1216–25.PubMedCrossRef
10.
go back to reference Holzapfel C, Baumert J, Grallert H, Muller AM, Thorand B, Khuseyinova N, et al. Genetic variants in the USF1 gene are associated with low-density lipoprotein cholesterol levels and incident type 2 diabetes mellitus in women: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Eur J Endocrinol. 2008;159(4):407–16.PubMedCrossRef Holzapfel C, Baumert J, Grallert H, Muller AM, Thorand B, Khuseyinova N, et al. Genetic variants in the USF1 gene are associated with low-density lipoprotein cholesterol levels and incident type 2 diabetes mellitus in women: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Eur J Endocrinol. 2008;159(4):407–16.PubMedCrossRef
11.
go back to reference Lee SK, Kim HJ, Kim BJ, Jo YS, Park KS, Baik HW, et al. Body mass index is associated with USF1 haplotype in Korean premenopausal women. J Korean Med Sci. 2008;23(1):83–8.PubMedCentralPubMedCrossRef Lee SK, Kim HJ, Kim BJ, Jo YS, Park KS, Baik HW, et al. Body mass index is associated with USF1 haplotype in Korean premenopausal women. J Korean Med Sci. 2008;23(1):83–8.PubMedCentralPubMedCrossRef
12.
go back to reference Naukkarinen J, Nilsson E, Koistinen HA, Soderlund S, Lyssenko V, Vaag A, et al. Functional variant disrupts insulin induction of USF1: mechanism for USF1-associated dyslipidemias. Circ Cardiovasc Genet. 2009;2(5):522–9.PubMedCrossRef Naukkarinen J, Nilsson E, Koistinen HA, Soderlund S, Lyssenko V, Vaag A, et al. Functional variant disrupts insulin induction of USF1: mechanism for USF1-associated dyslipidemias. Circ Cardiovasc Genet. 2009;2(5):522–9.PubMedCrossRef
13.
go back to reference Singmann P, Baumert J, Herder C, Meisinger C, Holzapfel C, Klopp N, et al. Gene-gene interaction between APOA5 and USF1: two candidate genes for the metabolic syndrome. Obes Facts. 2009;2(4):235–42.PubMedCentralPubMedCrossRef Singmann P, Baumert J, Herder C, Meisinger C, Holzapfel C, Klopp N, et al. Gene-gene interaction between APOA5 and USF1: two candidate genes for the metabolic syndrome. Obes Facts. 2009;2(4):235–42.PubMedCentralPubMedCrossRef
14.
go back to reference Chanda D, Li T, Song KH, Kim YH, Sim J, Lee CH, et al. Hepatocyte growth factor family negatively regulates hepatic gluconeogenesis via induction of orphan nuclear receptor small heterodimer partner in primary hepatocytes. J Biol Chem. 2009;284(42):28510–21.PubMedCentralPubMedCrossRef Chanda D, Li T, Song KH, Kim YH, Sim J, Lee CH, et al. Hepatocyte growth factor family negatively regulates hepatic gluconeogenesis via induction of orphan nuclear receptor small heterodimer partner in primary hepatocytes. J Biol Chem. 2009;284(42):28510–21.PubMedCentralPubMedCrossRef
15.
go back to reference Chen Q, Seol DW, Carr B, Zarnegar R. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology. 1997;26(1):59–66.PubMed Chen Q, Seol DW, Carr B, Zarnegar R. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology. 1997;26(1):59–66.PubMed
16.
go back to reference Desvergne B, Michalik L, Wahli W. Transcriptional regulation of metabolism. Physiol Rev. 2006;86(2):465–514.PubMedCrossRef Desvergne B, Michalik L, Wahli W. Transcriptional regulation of metabolism. Physiol Rev. 2006;86(2):465–514.PubMedCrossRef
17.
go back to reference van Deursen D, van Leeuwen M, Vaulont S, Jansen H, Verhoeven AJ. Upstream Stimulatory Factors 1 and 2 activate the human hepatic lipase promoter via E-box dependent and independent mechanisms. Biochim Biophys Acta. 2009;4:229–37.CrossRef van Deursen D, van Leeuwen M, Vaulont S, Jansen H, Verhoeven AJ. Upstream Stimulatory Factors 1 and 2 activate the human hepatic lipase promoter via E-box dependent and independent mechanisms. Biochim Biophys Acta. 2009;4:229–37.CrossRef
18.
19.
go back to reference Rearick D, Prakash A, McSweeny A, Shepard SS, Fedorova L, Fedorov A. Critical association of ncRNA with introns. Nucleic Acids Res. 2011;39(6):2357–66.PubMedCentralPubMedCrossRef Rearick D, Prakash A, McSweeny A, Shepard SS, Fedorova L, Fedorov A. Critical association of ncRNA with introns. Nucleic Acids Res. 2011;39(6):2357–66.PubMedCentralPubMedCrossRef
20.
go back to reference Laurila PP, Naukkarinen J, Kristiansson K, Ripatti S, Kauttu T, Silander K, et al. Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(2):346–52.PubMedCentralPubMedCrossRef Laurila PP, Naukkarinen J, Kristiansson K, Ripatti S, Kauttu T, Silander K, et al. Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(2):346–52.PubMedCentralPubMedCrossRef
21.
go back to reference Putt W, Palmen J, Nicaud V, Tregouet DA, Tahri-Daizadeh N, Flavell DM, et al. Variation in USF1 shows haplotype effects, gene : gene and gene : environment associations with glucose and lipid parameters in the European atherosclerosis research study II. Hum Mol Genet. 2004;13(15):1587–97.PubMedCrossRef Putt W, Palmen J, Nicaud V, Tregouet DA, Tahri-Daizadeh N, Flavell DM, et al. Variation in USF1 shows haplotype effects, gene : gene and gene : environment associations with glucose and lipid parameters in the European atherosclerosis research study II. Hum Mol Genet. 2004;13(15):1587–97.PubMedCrossRef
23.
go back to reference Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol. 2014;20(27):9072–89.PubMedCentralPubMed Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol. 2014;20(27):9072–89.PubMedCentralPubMed
24.
go back to reference Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta. 2010;3:299–310.CrossRef Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta. 2010;3:299–310.CrossRef
Metadata
Title
Two polymorphisms of USF1 gene (−202G>A and −844C>T) may be associated with hepatocellular carcinoma susceptibility based on a case–control study in Chinese Han population
Authors
Xu Zhou
Hua-qiang Zhu
Chao-qun Ma
Hong-guang Li
Fang-feng Liu
Hong Chang
Jun Lu
Publication date
01-12-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 12/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0301-4

Other articles of this Issue 12/2014

Medical Oncology 12/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.